Abstracts tagged "Biomarkers"

Abstract Number: 2026 • 2018 ACR/ARHP Annual Meeting
Calcium Crystal-Mediated Netosis in Juvenile Dermatomyositis and Anti-RNP+ Overlap Syndrome with Skin Involvement
Christian Lood¹, Gabrielle A. Morgan², Marisa Klein-Gitelman³, Megan L. Curran⁴ and Lauren M. Pachman⁵, ¹Department of Medicine, Division of Rheumatology, University of Washington, Seattle, WA, ²Cure JM Program of Excellence in Myositis Research, Stanley Manne Children’s Research Institute, affiliated with Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL, ³Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ⁴Section of Rheumatology, Children's Hospital of Colorado, Denver, CO, ⁵Cure JM Program of Excellence in Juvenile Myositis Research, Stanley Manne Children’s Research Institute, affiliated with Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL
Background/Purpose: Neutrophils are key immune cells participating in host defense through several mechanisms, including the formation of neutrophil extracellular traps (NETs). Although beneficial from a…
Abstract Number: 2920 • 2018 ACR/ARHP Annual Meeting
Correlations of Type I Interferon Score and Interferon Induced Chemokines CXCL10 and CXCL9 with Cutaneous and Muscular Disease Activity in Juvenile Dermatomyositis
Gian Marco Moneta¹, Ivan Caiello¹, Lucilla Rava'², Silvia Rosina³, Luisa Bracci Laudiero^1,4, Angelo Ravelli^3,5, Fabrizio De Benedetti⁶ and Rebecca Nicolai⁷, ¹Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Roma, Italy, ²Epidemiology Unit, IRCCS Ospedale Pediatrico Bambino Gesù, Roma, Italy, ³University of Genova, Genova, Italy, ⁴Institute of Translational Pharmacology, CNR, Roma, Italy, ⁵Rheumatology, Giannina Gaslini Institute, Genova, Italy, ⁶IRCCS Ospedale Pediatrico Bambino Gesù, Roma, Italy, ⁷Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy
Background/Purpose: Interferons (IFNs) seem to play an important role in the pathogenesis of juvenile dermatomyositis (JDM). We previously reported that expression of both type I…
Abstract Number: 776 • 2018 ACR/ARHP Annual Meeting
MMP7 and CXCL12: Two Promising Biomarkers in Lupus Nephritis
Sylvie Goletti^1,2, Séverine Nieuwland³, Frédéric A. Houssiau^2,3 and Bernard R. Lauwerys^2,3, ¹Service de Microbiologie, Cliniques Universitaires Saint-Luc, Brussels, Belgium, ²Pôle de pathologies rhumatismales systémiques et inflammatoires, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, Belgium, ³Rheumatology Department, Cliniques universitaires Saint-Luc, Brussels, Belgium
Background/Purpose: Lupus nephritis (LN) is one of the most serious complications of Systemic lupus erythematosus (SLE). Early diagnosis of renal impairment, combined with a strict…
Abstract Number: 1095 • 2018 ACR/ARHP Annual Meeting
IFN Gene Expression Correlates with Frequency of Circulating Switched Memory B-Cells in Patients with Incomplete Systemic Lupus Erythematosus
Wietske Lambers¹, Geert Lanting¹, Wayel H. Abdulahad², Hendrika Bootsma², Johanna Westra² and Karina de Leeuw³, ¹Rheumatology/Clinical Immunology, University Medical Center Groningen, Groningen, Netherlands, ²Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ³Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, Netherlands
Background/Purpose: Incomplete systemic lupus erythematosus (iSLE) includes patients with typical features of SLE, who do not meet classification criteria. Still, up to 50% will develop…
Abstract Number: 1521 • 2018 ACR/ARHP Annual Meeting
Anti-IL-6 Therapy Modulates Leptin in Patients with Rheumatoid Arthritis
Sara Remuzgo-Martínez¹, Fernanda Genre¹, Verónica Pulito-Cueto¹, Verónica Mijares¹, Leticia Lera-Gómez¹, Jaime Calvo-Alén², Ricardo Blanco¹, Oreste Gualillo³, Javier Llorca⁴, Santos Castañeda⁵, Raquel Lopez-Mejías¹ and Miguel Angel González-Gay^1,6,7, ¹Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL, Santander, Spain, Santander, Spain, ²Rheumatology Department, Hospital Universitario Araba. Vitoria-Gasteiz, Alava, Spain, ³SERGAS (Servizo Galego de Saude) and IDIS (Instituto de Investigación Sanitaria de Santiago), The NEIRID Group (Neuroendocrine Interactions in Rheumatology and Inflammatory Diseases), Santiago University Clinical Hospital, Santiago de Compostela, Spain, Santiago de Compostela, Spain, ⁴Department of Epidemiology and Computational Biology, School of Medicine, University of Cantabria, and CIBER Epidemiología y Salud Pública (CIBERESP), IDIVAL, Santander, Spain, Santander, Spain, ⁵Hospital Universitario La Princesa, IIS-Princesa, Madrid, Spain, ⁶Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, ⁷School of Medicine, University of Cantabria, Santander, Spain, Santander, Spain
Background/Purpose: Leptin is an adipokine that plays an important role in the regulation of body weight and also participates in immune homeostasis and inflammatory processes1,2.…
Abstract Number: 2028 • 2018 ACR/ARHP Annual Meeting
Microwave and Magnetic (M2) Myocardial Proteomics in the Mouse Model of Kawasaki Disease Demonstrates Normalization of the Proteome after Interleukin-1 Inhibition, Potential Novel Biomarkers, and Suggests New Insights into Mechanism of Disease
Mark Gorelik¹, Carol Chase², Magali Noval Rivas³, Jean Patterson¹, Moshe Arditi³ and Thomas Forsthuber², ¹Immunology and Virology, Texas Biomedical Research Institute, San Antonio, TX, ²University of Texas San Antonio, San Antonio, TX, ³Pediatrics, Cedars Sinai, Beverly Hills, CA
Background/Purpose: Kawasaki disease (KD), a predominantly coronary vasculitis of childhood, remains the most common cause of acquired heart disease of childhood in the developed world,…
Abstract Number: 2933 • 2018 ACR/ARHP Annual Meeting
Non-Invasive Tape Sampling Reveals RNA Gene Clusters in Cutaneous Lupus Erythematosus That Discriminate Affected from Unaffected and Healthy Volunteer Skin
Joseph F. Merola¹, Wenting Wang², Carrie Wager³, Stefan Hamann², Xueli Zhang³, Alice Thai², Chris Roberts², Christina Lam⁴, Cristina Musselli², Galina Marsh², Dania Rabah², Catherine Barbey⁵, Nathalie Franchimont² and Taylor L. Reynolds², ¹Clinical Unit for Research Innovation & Trials, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Biogen, Cambridge, MA, ³Formerly of Biogen, Cambridge, MA, ⁴Boston University Medical School, Boston, MA, ⁵Biogen, Zug, Switzerland
Background/Purpose: Punch biopsy, the standard diagnostic and monitoring procedure for patients with cutaneous lupus erythematosus (CLE), impedes patient recruitment and follow up due to risk…
Abstract Number: 173 • 2017 ACR/ARHP Annual Meeting
Applying Urine Proteomics for Discovery of Lupus Nephritis Damage Biomarkers in a Pediatric Cohort
Jessica Turnier¹, Bruce Aronow², Kenneth Greis³, Michael Bennett⁴, Wendy Haffey³, Sherry Thornton⁵, Gaurav Gulati⁶, Michael Wagner⁷, David Witte⁸, Prasad Devarajan⁹ and Hermine I. Brunner¹⁰, ¹Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Computational Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³University of Cincinnati College of Medicine, Cincinnati, OH, ⁴Nephrology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁵Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁶Division of Immunology, Allergy and Rheumatology, University of Cincinnati College of Medicine, Cincinnati, OH, ⁷Biomedical Informatics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁸Pathology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁹Nephrology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ¹⁰Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: Non-invasive biomarkers of lupus nephritis (LN) damage are needed to guide treatment decisions and determine risk for kidney failure. Urinary proteomics has advanced as…
Abstract Number: 680 • 2017 ACR/ARHP Annual Meeting
Abnormalities in Complement System Are Related to Disease Severity in Systemic Lupus Erythematosus (SLE)
Cristina Arriens¹, Sonali Narain², Amit Saxena³, Christopher E. Collins⁴, Daniel J. Wallace⁵, Elena Massarotti⁶, John Conklin⁷, Roberta Alexander⁷, Kenneth C. Kalunian⁸, Chaim Putterman⁹, Rosalind Ramsey-Goldman¹⁰, Jill P. Buyon¹¹, Anca Askanase¹², Richard Furie², Susan Manzi¹³, Joseph Ahearn¹⁴, Arthur Weinstein¹⁵ and Thierry Dervieux⁷, ¹Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Northwell Health, Great Neck, NY, ³Rheumatology, NYU Langone Medical Center, New York, NY, ⁴Rheumatology, MedStar Washington Hospital Center, Washington, DC, ⁵Cedars-Sinai Medical Center, UCLA, Los Angeles, CA, ⁶Brigham and Women's Hospital, Boston, MA, ⁷Exagen Diagnostics, Inc., Vista, CA, ⁸Division of Rheumatology, Allergy and Immunology, UCSD School of Medicine, La Jolla, CA, ⁹Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, USA, Bronx, NY, ¹⁰FSM, Northwestern University, Chicago, IL, ¹¹Medicine, New York University School of Medicine, New York, NY, ¹²Rheumatology, Columbia University, New York, NY, ¹³Medicine, Allegheny Health Network, Pittsburgh, PA, ¹⁴Lupus Center of Excellence, West Penn Allegheny Health System, Pittsburgh, PA, ¹⁵Rheumatology, MedStar Washington Hospital Center/Georgetown University Medical Center, Washington, DC
Background/Purpose: We sought to evaluate the relationships between low complement C3 and C4 proteins, abnormal complement activation (cell-bound complement activation products [CB-CAPs]), and a Lupus…
Abstract Number: 1010 • 2017 ACR/ARHP Annual Meeting
Identification of Circulating Biomarkers of Disease Activity and Organ Involvement in ANCA-Associated Vasculitis By Targeted Proteomics
Jun Ishizaki¹, Ayako Takemori², Koichiro Suemori¹, Takuya Matsumoto¹, Yoko Akita¹, Masaki Yasukawa¹, Nobuaki Takemori² and Hitoshi Hasegawa¹, ¹Department of Hematology, Clinical Immunology and Infectious Diseases, Ehime University Graduate School of Medicine, Ehime, Japan, ²Division of Proteomics Research, Proteo-Science Center, Ehime University, Ehime, Japan
Background/Purpose: Targeted proteomics, which involves quantitative analysis of targeted proteins using selected reaction monitoring (SRM) mass spectrometry, has emerged as a new methodology for discovery…
Abstract Number: 1535 • 2017 ACR/ARHP Annual Meeting
Study of Potential Clinical and Biologic Predictors of Maintaining Good Response at 1 Year Follow-up, in Patients with Ankylosing Spondylitis Under Dose Reduction of TNFi Treatment
Mireia Moreno¹, Caridad Pontes², Ferran Torres³, Agusti Sellas-Fernandez⁴, Miriam Almirall⁵, Juan Carlos Torre-Alonso⁶, Teresa Clavaguera⁷, Carlos Rodriguez-Lozano⁸, Luis Francisco Linares⁹, Ana Urruticoechea-Arana¹⁰, Eduardo Collantes-Estevez¹¹, Rosa Morla¹², Delia Reina¹³, Eduardo Cuende¹⁴, Pedro Zarco¹⁵, Cruz Fernandez-Espartero¹⁶, Rosario García-Vicuña¹⁷, Jesus Sanz¹⁸, Xavier Juanola¹⁹, Antoni Vallano²⁰, Francisco J Blanco²¹, Raimon Sanmarti²², Gonzalo Calvo²³, Cristina Avendaño²⁴, Eugenio De Miguel²⁵, Roser Vives²⁶, Raul Veroz Gonzalez²⁷, Carlos Alberto Montilla-Morales²⁸ and Jordi Gratacos-Masmitja²⁹, ¹Rheumatology, Parc Tauli Hospital Universitari, Sabadell, Spain, ²Clinic Pharmacology, Parc Tauli Hospital Universitari. I3PT. UAB, Sabadell, Spain, ³Hospital Clinic de Barcelona, Barcelona, Spain, ⁴Rheumatology, Hospital Universitario Valle Hebron, Barcelona, Spain, ⁵Rheumatology, Hospital del Mar, Barcelona, Spain, ⁶H Monte Naranco, Oviedo, Spain, ⁷Rheumatology. Palamós Hospital, Rheumatologist, Catalonia, Spain, ⁸Rheumatology, Hospital Universitario Dr. Negrin, Gran Canaria, Spain, ⁹Rheumatology, Hospital Virgen de la Arrixaca. Murcia. Spain, Murcia, Spain, ¹⁰Rheumatology Department. Hospital Can Misses, IBIZA, Spain, ¹¹Rheumatology, IMIBIC-Hospital Universitario Reina Sofia, Cordoba, Spain, ¹²Rambla Vella, 14, Hospital La Tecla, Tarragona, Spain, ¹³Rheumatology, Hospital de Sant Joan Despí Moisès Broggi, Barcelona, Spain, ¹⁴University Hospital Príncipe de Asturias, Immune System Diseases, Rheumatology department, Alcalá de Henares, Madrid, Spain, ¹⁵H Fundación Alcorcón, Alcorcón, Spain, ¹⁶Rheumatology, Hospital de Mostoles, Madrid, Spain, ¹⁷Rheumatology, Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain, ¹⁸Rheumatology, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain, ¹⁹Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ²⁰Clinic pharmacology, Hospital Universitari Bellvitge, Barcelona, Spain, ²¹Servicio de Reumatología. Area Genomica. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC), A Coruña, Spain, ²²Arthritis Unit, Rheumatology Dpt, Hospital Clinic of Barcelona, Barcelona, Spain, ²³Clinic pharmacology, Hospital Clinic Barcelona, Barcelona, Spain, ²⁴Clinic pharmacology, Hospital Puerta de Hierro, Madrid, Spain, ²⁵Medicine, Universidad Autonoma Madrid, MADRID, Spain, ²⁶Clinic pharmacology, Parc Tauli Hospital Universitari. I3PT. UAB, Sabadell, Spain, ²⁷Hospital de Mérida, Mérida, Spain, ²⁸Hospital Clínico Universitario de Salamanca, Salamanca, Spain, ²⁹Rheumatology, Parc Tauli Hospital Universitari, Sabadell, Barcelona, Spain
Background/Purpose: Some clinical guidance recommends empirical TNFi dose reductions in AS patients despite lack of robust supportive evidence. Recently, we communicated that a strategy of…
Abstract Number: 2322 • 2017 ACR/ARHP Annual Meeting
Quantitative Proteomics Comparison of Children with Inactive and Active Uveitis
Sheila Angeles-Han¹, Duc Duong², Steven Yeh³, Purnima Patel⁴, Virginia Miraldi Utz⁵, Kirsten Jenkins⁶, Danielle Lowe⁷, Sampath Prahalad⁸ and Gary Holland⁹, ¹Pediatrics, Cincinnati Children's Hospital Medical Center and University of Cincinnati, Cincinnati, OH, ²Emory University, Atlanta, GA, ³Ophthalmology, Emory University School of Medicine, Atlanta, GA, ⁴Emory University School of Medicine, Atlanta, GA, ⁵Pediatric Ophthalmology, Cincinnati Children's Hospital Medical Center and University of Cincinnati, Cincinnati, OH, ⁶Children's Healthcare of Atlanta, Atlanta, GA, ⁷Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁸Emory University School of Medicine and Children's Healthcare of Atlanta, Atlanta, GA, ⁹Jules Stein Eye Institute, Jules Stein Eye Institute, University of California, Los Angeles, Los Angeles, CA
Background/Purpose: Children with chronic non-infectious uveitis are at high risk for sight-threatening complications and vision loss. No biomarker predicts uveitis development or treatment response. Aqueous…
Abstract Number: 2875 • 2017 ACR/ARHP Annual Meeting
Molecular Features Define Unique Sjögren’s Syndrome Patient Subsets
Judith A. James¹, Joel M. Guthridge², Hua Chen³, Rufei Lu³, Rebecka L. Bourn³, Alan N. Baer⁴, Ghaith Noaiseh⁵, Anne Parke⁶, Andreea Coca⁷, Tammy Utset⁸, Mark C. Genovese⁹, Teresa Aberle³, Daniel J. Wallace¹⁰, Karen Boyle¹¹, Lynette Keyes-Elstein¹², Nathalie Franchimont¹³, Eugene St. Clair¹⁴, Virginia Pascual¹⁵, Paul J. Utz¹⁶ and Kathy L. Sivils², ¹Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Medicine (Rheumatology), Johns Hopkins University School of Medicine, Baltimore, MD, ⁵University of Pittsburgh Medical Center, Pittsburgh, PA, ⁶University of Connecticut, Farmington, CT, ⁷University of Rochester Medical Center, Rochester, NY, ⁸University of Chicago, Chicago, IL, ⁹Stanford University Medical Center, Palo Alto, CA, ¹⁰UCLA, Beverly Hills, CA, ¹¹Rho Federal Systems, Inc, Chapel Hill, NC, ¹²Rho Federal Systems, Inc., Chapel Hill, NC, ¹³Biogen, Cambridge, MA, ¹⁴Department of Medicine, Duke University Medical Center, Durham, NC, ¹⁵Baylor Institute for Immunology Research, Baylor Research Institute, Dallas, TX, ¹⁶Medicine, Stanford University School of Medicine, Stanford, CA
Background/Purpose: Immunologic heterogeneity in primary Sjogren’s syndrome (pSS) poses a challenge when selecting a therapeutic for a given patients or when assembling patient cohorts for…
Abstract Number: 179 • 2017 ACR/ARHP Annual Meeting
Mass Spectrometry Imaging of Synovium: A Novel Approach to Classify the Rheumatoid and Psoriatic Arthritis Patients
Beatriz Rocha^1,2, Berta Cillero-Pastor³, Gert Eijkel³, Lennart R. Huizing³, Cristina Ruiz-Romero^1,4, Andrea Cuervo^5,6, Ron M A Heeren³, Juan D. Cañete^5,6 and Francisco J Blanco^1,6, ¹Rheumatology Division, ProteoRed/ISCIII Proteomics Group, INIBIC - Hospital Universitario de A Coruña, A Coruña, Spain, A Coruña, Spain, ²The Maastricht Multimodal Molecular Imaging Institute (M4I), Division of Imaging Mass Spectrometry, Maastricht University, The Netherlands, Masstricht, Netherlands, ³The Maastricht Multimodal Molecular Imaging Institute (M4I), Division of Imaging Mass Spectrometry, Maastricht University, The Netherlands, Maastricht, Netherlands, ⁴CIBER-BBN Instituto de Salud Carlos III, INIBIC-CHUAC, A Coruña, Spain., A Coruña, Spain, ⁵Arthritis Unit, Rheumatology Department, Hospital Clinic, IDIBAPS, Barcelona, Spain, Barcelona, Spain, ⁶RIER-RED de Inflamación y Enfermedades Reumáticas, INIBIC-CHUAC, A Coruña, Spain, A Coruña, Spain
Background/Purpose: Psoriatic arthritis (PsA) and Rheumatoid arthritis (RA) are immune-mediated chronic inflammatory diseases. Synovial membrane is the initial site of inflammation in PsA and RA…
Abstract Number: 681 • 2017 ACR/ARHP Annual Meeting
A Panel of Lupus Biomarkers for the Monitoring of Systemic Lupus Erythematosus: Performance Characteristics in Distinct SLE Cohorts
Joan T. Merrill¹, Thierry Dervieux², Jill P. Buyon³, Rosalind Ramsey-Goldman⁴, Kenneth C. Kalunian⁵, Chaim Putterman⁶, John Conklin², Richard Furie⁷ and Michelle Petri⁸, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Exagen Diagnostics, Inc., Vista, CA, ³Medicine, New York University School of Medicine, New York, NY, ⁴FSM, Northwestern University, Chicago, IL, ⁵Division of Rheumatology, Allergy and Immunology, UCSD School of Medicine, La Jolla, CA, ⁶Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, USA, Bronx, NY, ⁷Northwell Health, Great Neck, NY, ⁸Medicine (Rheumatology), Division of Rheumatology, Johns Hopkins University School of Medicine, MD, USA, Baltimore, MD
Background/Purpose: Antibody titers to double stranded DNA (anti-dsDNA) and complement C3 and C4 proteins have clinical utility in the routine monitoring of systemic lupus erythematosus…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].